<?xml version='1.0' encoding='utf-8'?>
<document id="30366371"><sentence text="Clinical Utility of Definitive Drug⁻Drug Interaction Testing in Primary Care." /><sentence text="Drug⁻drug interactions (DDIs) are a leading cause of morbidity and mortality" /><sentence text=" New tools are needed to improve identification and treatment of DDIs" /><sentence text=" We conducted a randomized controlled trial to assess the clinical utility of a new test to identify DDIs and improve their management" /><sentence text=" Primary care physicians (PCPs) cared for simulated patients presenting with DDI symptoms from commonly prescribed medications and other ingestants" /><sentence text=" All physicians, in either control or one of two intervention groups, cared for six patients over two rounds of assessment" /><sentence text=" Intervention physicians were educated on the DDI test and given access to these test reports when caring for their patients in the second round" /><sentence text=" At baseline, we saw no significant differences in making the DDI diagnosis (p = 0" /><sentence text="071) or DDI-related treatment (p = 0" /><sentence text="640) between control and intervention arms" /><sentence text=" By round two, providers who accessed the DDI test performed significantly better in making the DDI diagnosis (+41" /><sentence text="6%) and performing DDI-specific treatment (+12" /><sentence text="2%) than in the previous round, and were 9" /><sentence text="8 and 20" /><sentence text="4 times more likely to diagnose and identify the DDI (p &lt; 0" /><sentence text="001 for all)" /><sentence text=" The introduction of a definitive DDI test significantly increased identification, appropriate management, and counseling of DDIs among PCPs, which has the potential to improve clinical care" /><sentence text="" /></document>